Reference entry — NOT a sellable lane, NOT approved. The hottest emerging obesity molecule: it folds the CagriSema idea (GLP-1 + amylin) into one molecule, in both oral and injectable forms. Investigational; racing into Phase 3. No dosing published here.
Amycretin is Novo Nordisk's first-in-class unimolecular GLP-1 + amylin agonist — the CagriSema concept in a single molecule, developed as both a pill and a weekly injection. Early-phase data are striking (~24% weight loss subcutaneously at 36 weeks; ~13% with the oral form at just 12 weeks, beating semaglutide at that timepoint), and Novo is taking both forms straight to Phase 3 in 2026. But it is early-stage (Phase 1b/2a) and not approved anywhere — the impressive numbers still need Phase 3 confirmation.
- Everywhere — investigational, not approved. Not available by prescription or compounding outside clinical trials. - Gray market: "research" amycretin sold online is unapproved and unregulated — unknown purity/dose (and, being early-stage, authenticity is especially doubtful). - This venture: not a sellable lane — an investigational drug.
An honest grade per outcome — drawn from the evidence, not any catalogue. Hype and undemonstrated marketing claims grade low.
A credentialed reviewer (PharmD / PhD / MD) will be named before this entry is finalised. Until then, treat it as a working draft. Last updated July 2026 (fast-moving — re-check Phase 3 progress).
Grades reflect the published evidence, not our interest. No dosing, reconstitution, or administration is published for research compounds — that restraint is deliberate.
A neutral reference and a lawful-lane shop. Registered in Spain. Information for those who seek it — never promotion.
This site provides neutral scientific reference and sells only products lawful in your region. Nothing here is medical advice, a recommendation, or an offer to supply unapproved medicines. No dosing or administration is published for research compounds. Cosmetic peptides per Regulation (EC) 1223/2009. Unapproved injectable peptides are neither sold nor advertised in the EU (Directive 2001/83/EC, Title VIII). © 2026 Vallydia SL — Registered in Spain.